Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3928/23258160-20130313-02 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Scoping review of nonsurgical treatment options for macular holes.
Surv Ophthalmol
September 2024
Ophthalmology department, Royal Adelaide Hospital, Adelaide SA 5000, Australia; Machine Learning Division, Ophthalmic Research Laboratory, University of Adelaide, Adelaide SA 5005, Australia.
Article Synopsis
- - Macular holes (MH) are retinal defects that impact central vision, and while vitrectomy with inner limiting membrane (ILM) peel is the main treatment, non-surgical options are being explored to reduce surgical risks.
- - A literature review analyzed various non-surgical treatments for MH, including laser therapy, medications like NSAIDs and steroids, and intravitreal injections, identifying anatomical closure rates ranging from 36% to 84% depending on the treatment.
- - While non-surgical options show promise, especially for smaller MH, there's still limited evidence for routine use, and vitrectomy with ILM peel remains the most reliable method for treating full-thickness MH.
The efficacy and safety of ocriplasmin for patients with vitreous macular traction.
Acta Ophthalmol
February 2022
Department of Ophthalmology, Peking Union Medical, College Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Purpose: To estimate the efficacy and safety of ocriplasmin for patients with vitreous macular traction (VMT).
Methods: The PubMed, EMBASE and Ovid were searched up to May 2020 to identify related studies. Statistical analysis was conducted by R software version 3.
Prognostic Factors Associated with Ocriplasmin Efficacy for the Treatment of Symptomatic Vitreomacular Adhesion and Full-thickness Macular Hole: Analysis from Four Studies.
J Ophthalmic Vis Res
January 2021
Wills Eye Hospital, Philadelphia, Pennsylvania, USA.
Purpose: To assess the effect of patient baseline characteristics on the efficacy of ocriplasmin treatment for symptomatic vitreomacular adhesion (VMA) with full-thickness macular hole (FTMH) from phase 3/4 studies.
Methods: Patients with symptomatic VMA and FTMH at baseline and receiving ocriplasmin treatment 125 g were pooled from the MIVI-TRUST, OASIS, and ORBIT studies. Multivariable logistic regression analysis was used to evaluate whether patient baseline characteristics were predictors of having VMA resolution by Day 28 and FTMH closure by Month 6.
Effectiveness of ocriplasmin in real-world settings: A systematic literature review, meta-analysis, and comparison with randomized trials.
Acta Ophthalmol
September 2021
Eye Clinic Sulzbach, Knappschaft Hospital Saar, Sulzbach, Germany.
Purpose: Effectiveness of ocriplasmin for vitreomacular traction (VMT) varies depending on the presence of common ocular conditions and patient selection criteria. We carried out a systematic literature review and meta-analysis of ocriplasmin studies conducted in real-world settings (RWS) and compared outcomes with those from randomized controlled trials (RCTs).
Methods: We included prospective and retrospective studies from RWS documenting effectiveness of ocriplasmin in patients with VMT with or without MH, and RCTs of ocriplasmin versus control.
Mutational Analysis of Ocriplasmin to Reduce Proteolytic and Autolytic Activity in Pichia pastoris.
Biol Proced Online
December 2020
Medical Biotechnology Department, Faculty of Advanced Medical Science, Tabriz University of Medical Sciences, Tabriz, Iran.
Background: Ocriplasmin (Jetrea) is using for the treatment of symptomatic vitreomacular adhesion. This enzyme undergoes rapid inactivation and limited activity duration as a result of its autolytic nature after injection within the eye. Moreover, the proteolytic activity can cause photoreceptor damage, which may result in visual impairment in more serious cases.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!